Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone

Preclinical

BBoston Scientific Corporation

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Persistent Atrial FibrillationActive, not recruiting

Persistent Atrial FibrillationPreclinical

Active, not recruiting

Timeline

Expected Milestones

Q1 2028

PreclinicalActive, not recruiting

Persistent Atrial Fibrillation

NCT06096337

Clinical

Trials by Indication[1]

Persistent Atrial Fibrillation1 trial

A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation (PFA) Versus Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

Active, not recruiting·BBoston Scientific Corporation·Preclinical·NCT06096337·484 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Boston Scientific Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: BBoston Scientific Corporation

Related News